Dorit Di Gioia

583 total citations
33 papers, 372 citations indexed

About

Dorit Di Gioia is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Dorit Di Gioia has authored 33 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Dorit Di Gioia's work include Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (7 papers) and Cardiac tumors and thrombi (6 papers). Dorit Di Gioia is often cited by papers focused on Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (7 papers) and Cardiac tumors and thrombi (6 papers). Dorit Di Gioia collaborates with scholars based in Germany, Switzerland and United States. Dorit Di Gioia's co-authors include Volker Heinemann, P Stieber, Dorothea Nagel, Andrea Baur‐Melnyk, Doris Mayr, D. Nagel, M F Dresse, Ingo Bauerfeind, Michael Untch and Steffen Kahlert and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and Clinica Chimica Acta.

In The Last Decade

Dorit Di Gioia

25 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dorit Di Gioia Germany 10 200 118 111 95 81 33 372
Mohamed M. Kahila United States 7 205 1.0× 126 1.1× 65 0.6× 121 1.3× 49 0.6× 15 373
George Horng United States 9 139 0.7× 130 1.1× 90 0.8× 69 0.7× 92 1.1× 12 344
Joseph Sia Australia 8 143 0.7× 105 0.9× 191 1.7× 64 0.7× 112 1.4× 24 421
Hao Hu China 13 244 1.2× 151 1.3× 176 1.6× 100 1.1× 56 0.7× 43 545
Giacomo Barchiesi Italy 11 232 1.2× 108 0.9× 96 0.9× 88 0.9× 44 0.5× 22 376
Alex De Caluwé Belgium 9 305 1.5× 104 0.9× 196 1.8× 100 1.1× 46 0.6× 25 523
Joanna Niemiec Poland 14 243 1.2× 114 1.0× 163 1.5× 134 1.4× 124 1.5× 47 462
Nicolas Piton France 14 184 0.9× 98 0.8× 310 2.8× 116 1.2× 48 0.6× 43 539
Jeremy Sharib United States 14 242 1.2× 85 0.7× 130 1.2× 65 0.7× 58 0.7× 24 413
Andrea Emanuele Guerini Italy 9 119 0.6× 76 0.6× 102 0.9× 44 0.5× 61 0.8× 33 370

Countries citing papers authored by Dorit Di Gioia

Since Specialization
Citations

This map shows the geographic impact of Dorit Di Gioia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorit Di Gioia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorit Di Gioia more than expected).

Fields of papers citing papers by Dorit Di Gioia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dorit Di Gioia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorit Di Gioia. The network helps show where Dorit Di Gioia may publish in the future.

Co-authorship network of co-authors of Dorit Di Gioia

This figure shows the co-authorship network connecting the top 25 collaborators of Dorit Di Gioia. A scholar is included among the top collaborators of Dorit Di Gioia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorit Di Gioia. Dorit Di Gioia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jurinović, Vindi, S. Abdel-Rahman, Markus Albertsmeier, et al.. (2025). Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis. Cancer Medicine. 14(4). e70655–e70655. 3 indexed citations
2.
Gioia, Dorit Di, Vindi Jurinović, Stefanie Corradini, et al.. (2025). Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich. Cardio-Oncology. 11(1). 58–58.
3.
4.
Jurinović, Vindi, Markus Albertsmeier, Hans Roland Dürr, et al.. (2025). First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysis. Journal of Cancer Research and Clinical Oncology. 151(4). 150–150.
5.
Gioia, Dorit Di, Vindi Jurinović, Markus Albertsmeier, et al.. (2025). LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatment. BMC Cancer. 25(1). 496–496. 3 indexed citations
6.
Lechner, Axel, Sultan Abdel-Rahman, Wolfgang G. Kunz, et al.. (2025). Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinoma. Cancer Immunology Immunotherapy. 74(6). 174–174. 1 indexed citations
7.
Gioia, Dorit Di, Vindi Jurinović, Alexander Klein, et al.. (2025). The impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in patients with high-risk soft tissue sarcoma. BMC Cancer. 25(1). 671–671.
8.
Klein, Alexander, et al.. (2024). Surgical site infections after sarcoma resections in the peripelvic region: do we need perioperative antibiotic prophylaxis?. Frontiers in Oncology. 14. 1467694–1467694. 1 indexed citations
9.
Lange, Philipp, Dorit Di Gioia, M. Schmidt, et al.. (2023). Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience. Journal of Cancer Research and Clinical Oncology. 149(15). 13973–13983. 3 indexed citations
10.
Altendorf-Hofmann, A., Lars H. Lindner, Dorit Di Gioia, et al.. (2023). TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS). Cancers. 15(10). 2735–2735. 3 indexed citations
11.
Dorman, Klara, Dorit Di Gioia, Wolfgang G. Kunz, et al.. (2022). Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disorders. Anti-Cancer Drugs. 34(2). 311–316. 3 indexed citations
12.
Klein, Alexander, et al.. (2022). Sarcomas of the extremities and the pelvis: comparing local recurrence after incisional and after core-needle biopsy. World Journal of Surgical Oncology. 20(1). 14–14. 4 indexed citations
13.
Altendorf-Hofmann, A., Hans Roland Dürr, Alexander Klein, et al.. (2021). Expression Patterns of TOP2A and SIRT1 Are Predictive of Survival in Patients with High-Risk Soft Tissue Sarcomas Treated with a Neoadjuvant Anthracycline-Based Chemotherapy. Cancers. 13(19). 4877–4877. 9 indexed citations
14.
15.
16.
Stieber, P, Dorothea Nagel, Volker Heinemann, et al.. (2015). Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients. Clinica Chimica Acta. 448. 228–231. 53 indexed citations
17.
Gießen-Jung, Clemens, Dorothea Nagel, F. Spelsberg, et al.. (2015). Preoperative serum markers for individual patient prognosis in stage I–III colon cancer. Tumor Biology. 36(10). 7897–7906. 34 indexed citations
18.
Gioia, Dorit Di, M F Dresse, Doris Mayr, et al.. (2014). Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clinica Chimica Acta. 440. 16–22. 48 indexed citations
19.
Gioia, Dorit Di, M F Dresse, Doris Mayr, et al.. (2014). Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clinica Chimica Acta. 430. 86–91. 18 indexed citations
20.
Heinemann, Volker, Dorit Di Gioia, Ursula Vehling‐Kaiser, et al.. (2010). A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Annals of Oncology. 22(3). 603–608. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohamed M. Kahila Breakdown of academic impact, for papers by George Horng Breakdown of academic impact, for papers by Joseph Sia Breakdown of academic impact, for papers by Hao Hu Breakdown of academic impact, for papers by Giacomo Barchiesi Breakdown of academic impact, for papers by Alex De Caluwé Breakdown of academic impact, for papers by Joanna Niemiec Breakdown of academic impact, for papers by Nicolas Piton Breakdown of academic impact, for papers by Jeremy Sharib Breakdown of academic impact, for papers by Andrea Emanuele Guerini
Rankless by CCL
2026